Sanofi (SNY,SAN.PA) said phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. In both studies, lunsekimig was well tolerated, with an acceptable safety profile. Detailed results from the AIRCULES, DUET, and VELVET studies will be presented at upcoming medical congresses.
The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status. The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps. The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.